Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome

Lupus

Volumn 16, Issue 7, 2007, Pages 497-503

  Der, H ^a   Kerekes, G ^a   Veres, K ^a   Szodoray, P ^a   Toth, J ^a   Lakos, G ^a   Szegedi, G ^a,b   Soltesz, Pal ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Endothelium dependent vasodilation; Primary antiphospholipid syndrome; Von Willebrand factor

Indexed keywords

NITRATE; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; VASODILATATION;

ADMINISTRATION, SUBLINGUAL; ANTIGENS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; NITROGLYCERIN; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VASODILATION; VASODILATOR AGENTS;

EID: 34547800738     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307080224     Document Type: Article

References (43)

1. Kelm M. Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. Am J Physiol Heart Circ Physiol 2002; 282: 1-5.
2. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
3. Sorensen KE, Celermajer DS, Spiegelhalter DJ et al. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247-253.
4. Neunteufl T, Katzenschlager R, Hassan A et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-118.
5. Schachinger V, Zeiher AM. Atherosclerosis-associated endothelial dysfunction. Z Kardiol 2000; 89: 70-74.
6. Britten M, Schachinger V. The role of endothelial function for ischemic manifestations of coronary atherosclerosis. Herz 1998; 23: 97-105.
7. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005; 45: 1980-1986.
8. Gordon PA, George J, Khamashta MA, Harats D, Hughes G, Shoenfeld Y. Atherosclerosis and autoimmunity. Lupus 2001; 10: 249-252.
9. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 2000; 3: 223-227.
10. Wilson AE, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 7: 1309-1311.
11. Meroni PL, Raschi E, Testoni C. Endothelium as a target for antiphospholipid antibodies and for therapeutical intervention. Autoimmun Rev 2002; 1-2: 55-60.
12. Riboldi P, Gerosa M, Raschi E, Testoni C, Meroni PL. Endothelium as a target for antiphospholipid antibodies. Immunobiology 2003; 1: 29-36.
13. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, antiphospholipid antibodies, and atherosclerosis. Curr Atheroscler Rep 2001; 4: 328-333.
14. Baron MA, Khamashta MA, Hughes GR, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64: 144-146.
15. George J, Shoenfeld Y, Harats D. The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis. J Autoimmun 1999; 13: 57-60.
16. George J, Harats D, Gilburd B et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999; 99: 2227-2230.
17. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis 2006; 4: 295-306.
18. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Seminars Thromb Haemost 1999; 25: 333-350.
19. Corretti MC, Anderson TJ, Benjamin EJ et al., International brachial artery reactivity task force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2002; 39: 257-265.
20. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation a diagnostic instrument or an experimental tool? Chest 2005; 127: 2254-2263.
21. Kanters SDJM, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements. Stroke 1997; 28: 665-671.
22. Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005; 12: 1215-1220.
23. Riboldi P, Gerosa M, Luzzana C, Catelli L. Cardiac involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol 2002; 23: 247-261.
24. Jara LJ, Medina G, Vera-Lastra O, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006; 5: 195-201.
25. Roman MJ, Shanker BA, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.
26. Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071-1077.
27. Jara LJ, Medina G, Vera-Lastra O, Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25: 79-87.
28. Kiss E, Soltesz P, Der H et al. Reduced flow-mediated vasodilation is a good marker of cardiovascular complications in lupus patients. Autoimmun 2006; 27: 211-217.
29. George J, Blank M, Levy Y et al. Differential effects of anti-β2 GPI antibodies on endothelial cells and on the manifestations of experimental anthiphospholipid syndrome. Circulation 1998; 97: 900-906.
30. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannacone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002; 11: 208-214.
31. Meroni PL, Borghi MO, Raschi E et al. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-34.
32. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64: 315-317.
33. Vlachoyiannopoulus PG, Kanellopoulus PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 2003; 42: 645-651.
34. Medina G, Casaos D, Jara LJ et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 607-610.
35. Shoenfeld Y, Harats D, George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled? Lupus 1998; 7(Suppl): 140-143.
36. Jimenez S, Garcia-Criado MA, Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44: 756-761.
37. Shoenfeld Y, Wu R, Dearing L, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110: 2552-2558.
38. Lima DS, Sato L, Lima VC, Miranda F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosis. J Rheumatol 2002; 29: 2006-2011.
39. Thompson SG, Kienast J, Pyke SD Haverkate F, van de Loo JC. Hemostatic factors the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
40. Jansson JH, Nilsson TK, Johnson O. Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
41. Oosting JD, Derksen RH, Bobbink IW et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-2625.
42. Meroni PL, Borghi MO, Raschi E et al. Inflammatory response and the endothelium. Thromb Res 2004; 114: 329-334.
43. Tikiz C, Utuk O, Pirildar T et al. Effects of angiotensin- converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005; 32: 2095-2101.